<DOC>
	<DOC>NCT00193063</DOC>
	<brief_summary>Due to its remarkable activity as salvage treatment in women with metastatic breast cancer as well as the additive activity observed for gemcitabine administered in combination with trastuzumab, the clinical activity of the combination of gemcitabine administered with trastuzumab represents an exciting and ideal combination to further evaluate in Her 2 over-expressing metastatic breast cancer patients.</brief_summary>
	<brief_title>Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer</brief_title>
	<detailed_description>Upon determination of eligibility, all patients will be receive: Gemcitabine + Trastuzumab</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>To be included in this study, you must meet the following criteria: Her2 positive metastatic breast cancer confirmed by biopsy Measurable disease Able to perform activities of daily living without considerable No previous chemotherapy with gemcitabine No more than one prior chemotherapy regimen for metastatic breast cancer Adequate bone marrow, liver and renal function Normal heart function Give written informed consent prior to entering this study. You cannot participate in this study if any of the following apply to you: Received previous treatment with gemcitabine History of brain metastases Serious underlying medical conditions Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>